Treating inflammatory bowel disease (IBD) with tumor necrosis factor (TNF) inhibitors was paradoxically associated with an increased risk for other immune-mediated inflammatory diseases (IMIDs) in a ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Among older ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase (JAK) inhibitors than with tumor necrosis factor (TNF) inhibitors, ...

Among biologic agents, vedolizumab (Entyvio) and ustekinumab (Stelara) are associated with lower rates of infection-related hospitalizations than anti-tumor necrosis factor (TNF) agents in older ...

Please provide your email address to receive an email when new articles are posted on . Mirikizumab, a monoclonal antibody poised to become first-in-class treatment for ulcerative colitis, has the ...

Senior man has stomachache Researchers compared the difference in overall health care utilization in patients with IBD who started anti-TNF therapy 2 years vs more than 2 years postdiagnosis. Early ...

Patients with inflammatory bowel disease (IBD) face a higher risk for complications of herpes zoster than those without IBD, with older age, higher comorbidity scores, and management with anti–tumor ...

A growth factor protein produced by rare immune cells in the intestine can protect against the effects of inflammatory bowel disease (IBD), according to a new discovery from Weill Cornell Medicine ...

DALLAS--(BUSINESS WIRE)--EnLiSense CCM, a pioneer in non-invasive, real-time inflammatory biomarker monitoring, announces the initiation of multiple groundbreaking clinical studies in collaboration ...